Aimovig erenumab logo
Neuroscience
AIMOVIG® (erenumab)
Cosentyx secukinumab logo
Dermatology
Cosentyx® (secukinumab)
Cosentyx secukinumab logo
Rheumatology
Cosentyx® (secukinumab)
Fabhalta iptacopan logo
Haematology
FABHALTA®▼ (iptacopan)
Ilaris canakinumab logo
Immunology
ILARIS® (canakinumab)
Jakavi ruxolitinib logo
Haematology
JAKAVI® (ruxolitinib)
Kesimpta ofatumumab logo
Neuroscience
KESIMPTA®▼ (ofatumumab)
Leqvio inclisiran logo
Cardio-metabolic
LEQVIO®▼ (inclisiran)
Lutathera logo
 
LUTATHERA® (lutetium [177Lu] oxodotreotide)
Pluvicto logo
 
Pluvicto®▼ (lutetium [177Lu] vipivotide tetraxetan)
 TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) logo
Oncology
TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) in melanoma
 TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) logo
Oncology
TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) in Non-Small Cell Lung Cancer (NSCLC)
XOLAIR® (omalizumab) logo
Dermatology
XOLAIR® (omalizumab)
Xolair Logo
Respiratory and Inflammation
Xolair® (omalizumab)

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.